Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...
Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects
Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.
Rick Doblin, Recently Visited one of Psycheceutical's Labs.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted...
Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.
We Liked it at $3.50, we Love it at $2.25.
Down but not out. Now trading below the...
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
